Any current/future capex/capital investment/strategic investment?

Morepen Laboratories does not have any major capex currently planned; ongoing capex is divided between working capital and capital expenditure (Page 22). The company's growth is primarily funded through internal accruals and capital from warrant subscription, without bank borrowings (Page 22). Working capital requirements are increasing due to growth, and this constrains the ability to invest heavily in capex (Page 18). The company is open to exploring investment opportunities but hasn't closed any specific proposals yet (Page 14). For medical devices, expansion involves adding new products li

Future growth expectations in sales/revenue/volumes?

Health and pharmaceutical business is growing exponentially with no anticipated market decline. Long-term focus includes API development, power integration, new segments, and increased exports. Expectations for business stabilization may take 1-2 more quarters to return to desired growth. Medical devices, especially Glucometers and BP monitors, expected to drive growth over next 3-4 quarters. Finished dosage business growing steadily with 28% yearly increase; strong growth in antibiotics, probiotics, nutrition, and OTC segments. Online OTC business rapidly expanding, growing 273% in small base

Future growth expectations in earnings/operating earnings/profits/EPS?

Health and pharmaceutical business is growing exponentially and expected to continue expanding. Long-term focus on APIs, power integration, new segments, and export of APIs and ANDAs. Short-term stabilization of quarterly numbers may take 1-2 more quarters before returning to desired growth. International market expansion is planned post obtaining necessary certifications. Medical devices growth driven mainly by glucometers and BP monitors with 40-47% CAGR. EBITDA showed around Rs. 130 crores, but cash flow impacted by increased working capital; expected to improve in coming quarters. Operatin

Current/ Expected Orderbook/ Pending Orders?

The transcript on pages 12-23 does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited. However, it is indicated that the company is working on long-term projects such as exporting APIs, filing ANDAs, and expanding product segments, suggesting a healthy pipeline. There is an emphasis on market stabilization expected to take one to two more quarters before growth trends normalize. The domestic business and exports are growing, with an ongoing focus on increasing market share in key products. Investments in inventory and receivables indica

Any current/future new fundraising through debt or equity?

Morepen Laboratories has not closed any new investment proposal yet; they remain open to financing options but have not finalized any fundraising. The company is a zero-debt entity currently and has no borrowings. They face constraints growing working capital since they rely mainly on internal accruals and have not taken bank working capital loans, partly due to their CDR tag and preference capital issue limiting bank support for borrowings. Future growth strategies include finding solutions for working capital needs, possibly through better financing arrangements. Promoters have recen

Morepen Laboratories LtdQ4 FY22Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Health and pharmaceutical business is growing exponentially with no anticipated market decline.
Long-term focus includes API development, power integration, new segments, and increased exports.
Expectations for business stabilization may take 1-2 more quarters to return to desired growth.
Medical devices, especially Glucometers and BP monitors, expected to drive growth over next 3-4 quarters.
Finished dosage business growing steadily with 28% yearly increase; strong growth in antibiotics, probiotics, nutrition, and OTC segments.
Online OTC business rapidly expanding, growing 273% in small base.
Export market focus with regulatory approvals sought to expand international presence.
Product portfolio expansion ongoing, including post-patent products like Sitagliptin.
Market competition expected, but growth opportunities remain strong due to "Make in India" and PLI schemes.
Operating margins targeted to improve from Q1 onwards, aiming to maintain previous 7-10% range.

Margin guidance

Category 3

Health and pharmaceutical business is growing exponentially and expected to continue expanding.
Long-term focus on APIs, power integration, new segments, and export of APIs and ANDAs.
Short-term stabilization of quarterly numbers may take 1-2 more quarters before returning to desired growth.
International market expansion is planned post obtaining necessary certifications.
Medical devices growth driven mainly by glucometers and BP monitors with 40-47% CAGR.
EBITDA showed around Rs. 130 crores, but cash flow impacted by increased working capital; expected to improve in coming quarters.
Operating margins have declined recently (from around 10-11% to 5%) due to competitive pressures, expected to stabilize around 7-8%.
Dividend declarations depend on resolution of preference share matters; planning for dividend policy in the near future.
Overall, confident of sustained revenue growth with improving margins and profitability over next 2-3 years.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Morepen Laboratories has not closed any new investment proposal yet; they remain open to financing options but have not finalized any fundraising.
The company is a zero-debt entity currently and has no borrowings.
They face constraints growing working capital since they rely mainly on internal accruals and have not taken bank working capital loans, partly due to their CDR tag and preference capital issue limiting bank support for borrowings.
Future growth strategies include finding solutions for working capital needs, possibly through better financing arrangements.
Promoters have recently subscribed to warrants worth Rs. 2.8 crores as part of capital raise.
No concrete plans announced for major debt or equity fundraises as of the date (May 6, 2022), but they remain open to investment opportunities for growth.

Order book

Yes

The transcript on pages 12-23 does not explicitly mention the current or expected order book or pending orders for Morepen Laboratories Limited.
However, it is indicated that the company is working on long-term projects such as exporting APIs, filing ANDAs, and expanding product segments, suggesting a healthy pipeline.
There is an emphasis on market stabilization expected to take one to two more quarters before growth trends normalize.
The domestic business and exports are growing, with an ongoing focus on increasing market share in key products.
Investments in inventory and receivables indicate preparation to meet existing and anticipated demand.
International expansion plans are also underway, contingent on receiving necessary certifications.
Overall, while specific order book figures are not disclosed, business momentum and strategic initiatives imply a steady or growing order flow.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Morepen Laboratories does not have any major capex currently planned; ongoing capex is divided between working capital and capital expenditure (Page 22).
The company's growth is primarily funded through internal accruals and capital from warrant subscription, without bank borrowings (Page 22).
Working capital requirements are increasing due to growth, and this constrains the ability to invest heavily in capex (Page 18).
The company is open to exploring investment opportunities but hasn't closed any specific proposals yet (Page 14).
For medical devices, expansion involves adding new products like nebulizers, weighing scales, and air purifiers, with licenses and production capacity being worked on—some products may be launched by September quarter (Page 19).
International market expansion in medical devices is planned, pending certifications and audits (Page 19).

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 2Mar 3

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →